Welcome to our dedicated page for Bio-Key Intl news (Ticker: BKYI), a resource for investors and traders seeking the latest updates and insights on Bio-Key Intl stock.
BIO-key International, Inc. (NASDAQ: BKYI) is an identity and access management (IAM) and biometric authentication company whose news flow centers on product innovation, strategic partnerships, investor communications, and capital markets activity. Press releases describe BIO-key as a biometric-centric, multi-factor IAM provider enabling phoneless, tokenless, passwordless, and phishing-resistant authentication for enterprise and large-scale identity deployments.
On this page, readers can follow updates on BIO-key’s participation in industry conferences and investor events, such as the Gartner Identity & Access Management Summit, the Africa Tech Festival, and the DealFlow Discovery investor conference. These announcements often highlight new passwordless capabilities, identity-bound biometric technologies, and demonstrations of the PortalGuard IAM platform.
Company news also covers strategic partnerships that extend BIO-key’s reach in key regions. Recent releases describe collaborations with SAVIS Group in Vietnam, VaporVM in the Middle East and Africa, and Cloud Distribution in Saudi Arabia. Through these relationships, BIO-key’s IAM and biometric solutions are integrated into broader cybersecurity and digital transformation offerings for enterprises, government agencies, and institutions.
Investors can track earnings-related communications and balance sheet updates through quarterly results announcements and associated investor calls. BIO-key’s news includes details on hardware launches such as the EcoID III fingerprint scanner, as well as disclosures about warrant exercise agreements and secured promissory notes that affect the company’s capital structure.
By monitoring the BKYI news feed, users can see how BIO-key positions its biometric and IAM technologies in sectors such as defense, finance, government, and education, and stay informed about material events reported in press releases that complement the company’s formal SEC filings.
BIO-key (Nasdaq: BKYI) announced a 1-for-10 reverse stock split effective with the opening of trading on April 30, 2026. The company had ~10.9 million shares outstanding as of April 28, 2026; post-split it will have ~1.1 million shares outstanding.
The Board approved the ratio after stockholder approval to assist BIO-key in regaining compliance with the Nasdaq minimum bid price requirement. According to the company, management is executing growth goals that include achieving profitability in the first half of 2026.
BIO-key (Nasdaq: BKYI) received a Notice of Non-Compliance from Nasdaq for failing to timely file its Annual Report on Form 10-K for the year ended December 31, 2025 under Nasdaq Rule 5250(c)(1).
The notice does not immediately affect listing or trading. The company is working with auditors and expects to file the Form 10-K next week.
BIO-key (Nasdaq: BKYI) expects 1H 2026 revenue of approximately $5.0M, up ~50% from $3.3M in 1H 2025, driven by software license momentum and stronger hardware sales.
The company expects positive net income in 1H 2026 versus a $1.9M loss in 1H 2025, a stable cash balance near $2.7M, and specific wins including a $1.04M one-year software renewal and over $1M in hardware contracts.
BIO-key (Nasdaq: BKYI) reported 2025 revenue of $6.1M, preliminary Q1’26 revenue of $2.2M (up 37% vs Q1’25), and year-end cash of $2.7M. BIO-key cited defense, financial, and international partner traction, hardware growth, reduced SG&A, and an expectation of stronger 2026 results while noting the 2025 audit is not yet complete.
BIO-key (NASDAQ: BKYI) will host its 2025 year-end investor call on Tuesday, March 31, 2026 at 10:00 a.m. ET, with results released prior to market open. The call will be led by Mike DePasquale, Chairman & CEO, and Cecilia Welch, CFO, and will include a Q&A session.
Dial-in numbers, webcast/replay availability for three months, and audio replay details are provided for investors.
BIO-key (NASDAQ: BKYI) announced a strategic partnership with TD SYNNEX Public Sector (DLT) on March 12, 2026 to deliver identity-bound biometric and IAM solutions to U.S. federal, state, and local agencies. The collaboration integrates PortalGuard and Passkey:YOU into DLT contract vehicles to simplify procurement and support Zero Trust, phishing-resistant MFA, and compliance with CJIS, HIPAA, and NIST SP 800-171.
Key capabilities include NIST-tested, FBI-certified fingerprint biometrics, centralized SSO/IDaaS via PortalGuard, multi-factor authentication across 20+ methods, and self-service tools to reduce help-desk costs.
BIO-key (NASDAQ: BKYI) reported a new $280,000 order from a foreign defense ministry, bringing that customer's bookings to $1.14M in the past 12 months and BIO-key's total military/defense orders to over $2M in the last year.
The company highlights demand for phoneless, tokenless biometric authentication for SCIF and FME environments, support for more than 50,000 licensed users at the customer, and certifications including NIST, FBI FAP and FIPS 201.
BIO-key (NASDAQ: BKYI) secured a $1.04M one-year license renewal and expansion from a foreign retail bank on March 3, 2026, a 30% increase versus prior year. The company reports $2.7M year-end cash and expects receivables and renewals to fund growth internally. Deployment has grown from 7M enrolled clients in 2015 to over 30M today (≈300M fingerprints); the renewal anticipates 5% client enrollment growth and notes ~10,000 bank employees use the fingerprint system.
BIO-key (NASDAQ: BKYI) announced a multi-year agreement with Sociedade Interbancária de Moçambique (SIMO) on Feb. 24, 2026 to modernize identity and access security across Mozambique’s national payments network.
Integration will deploy PortalGuard IAM, PIN:You tokenless authentication and SSO via partner RunLevel, building on a May 2025 pilot and marking BIO-key’s 11th banking customer globally.
BIO-key (NASDAQ: BKYI) announced a planned Mumbai office launch and a strategic value‑added distributor partnership with Citadel Global to expand its India presence, led by BIO-key EMEA, dated Jan 29, 2026. The initiative targets large enterprises, financial institutions, and call centers and aligns with the EU–India free trade agreement to accelerate biometric IAM adoption. Citadel will provide pre-sales, deployment, training, and customer success support while BIO-key’s portfolio (PortalGuard, Passkey:YOU, Identity‑Bound Biometrics, WEB-key) will be delivered via Citadel’s local infrastructure.